News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,362 Results
Type
Article (43003)
Company Profile (285)
Press Release (688063)
Multimedia
Podcasts (86)
Webinars (20)
Section
Business (206136)
Career Advice (2048)
Deals (35738)
Drug Delivery (120)
Drug Development (82351)
Employer Resources (173)
FDA (16534)
Job Trends (15021)
News (349031)
Policy (32877)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2637)
Accelerated approval (38)
Adcomms (26)
Allergies (156)
Alliances (50222)
ALS (193)
Alzheimer's disease (1736)
Antibody-drug conjugate (ADC) (363)
Approvals (16822)
Artificial intelligence (589)
Autoimmune disease (214)
Automation (46)
Bankruptcy (363)
Best Places to Work (11685)
BIOSECURE Act (20)
Biosimilars (198)
Biotechnology (187)
Bladder cancer (175)
Brain cancer (65)
Breast cancer (680)
Cancer (5223)
Cardiovascular disease (444)
Career advice (1729)
Career pathing (38)
CAR-T (294)
CDC (51)
Celiac Disease (2)
Cell therapy (791)
Cervical cancer (40)
Clinical research (70670)
Collaboration (1870)
Company closure (4)
Compensation (1248)
Complete response letters (71)
COVID-19 (2746)
CRISPR (100)
C-suite (945)
Cystic fibrosis (146)
Data (6815)
Decentralized trials (2)
Denatured (26)
Depression (152)
Diabetes (540)
Diagnostics (6816)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (284)
Drug pricing (194)
Drug shortages (28)
Duchenne muscular dystrophy (266)
Earnings (91038)
Editorial (60)
Employer branding (21)
Employer resources (152)
Events (119134)
Executive appointments (1022)
FDA (19859)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1582)
Gene editing (211)
Generative AI (47)
Gene therapy (650)
GLP-1 (1037)
Government (4704)
Grass and pollen (6)
Guidances (391)
Healthcare (19044)
HIV (70)
Huntington's disease (54)
IgA nephropathy (88)
Immunology and inflammation (281)
Immuno-oncology (78)
Indications (148)
Infectious disease (3049)
Inflammatory bowel disease (206)
Inflation Reduction Act (15)
Influenza (124)
Intellectual property (271)
Interviews (320)
IPO (16726)
IRA (53)
Job creations (3665)
Job search strategy (1444)
JPM (59)
Kidney cancer (18)
Labor market (91)
Layoffs (561)
Leadership (33)
Legal (7974)
Liver cancer (94)
Longevity (24)
Lung cancer (697)
Lymphoma (397)
Machine learning (51)
Management (59)
Manufacturing (886)
MASH (180)
Medical device (13854)
Medtech (13926)
Mergers & acquisitions (20139)
Metabolic disorders (1403)
mRNA (178)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (371)
Neuropsychiatric disorders (96)
Neuroscience (3103)
Neurotech (1)
NextGen: Class of 2026 (6590)
Non-profit (4543)
Now hiring (72)
Obesity (667)
Opinion (284)
Ovarian cancer (176)
Pain (222)
Pancreatic cancer (248)
Parkinson's disease (326)
Partnered (34)
Patents (541)
Patient recruitment (562)
Peanut (60)
People (59503)
Pharmaceutical (63)
Pharmacy benefit managers (30)
Phase 1 (22106)
Phase 2 (31105)
Phase 3 (23116)
Pipeline (6556)
Policy (306)
Postmarket research (2577)
Preclinical (9461)
Press Release (64)
Prostate cancer (272)
Psychedelics (50)
Radiopharmaceuticals (304)
Rare diseases (972)
Real estate (5995)
Recruiting (70)
Regulatory (24937)
Reports (54)
Research institute (2443)
Resumes & cover letters (360)
Rett syndrome (32)
RNA editing (18)
RSV (83)
Schizophrenia (158)
Series A (265)
Series B (199)
Service/supplier (11)
Sickle cell disease (103)
Special edition (23)
Spinal muscular atrophy (161)
Sponsored (43)
Startups (3684)
State (2)
Stomach cancer (19)
Supply chain (114)
Tariffs (85)
The Weekly (58)
Vaccines (1044)
Venture capital (96)
Weight loss (427)
Women's health (106)
Worklife (19)
Date
Today (45)
Last 7 days (575)
Last 30 days (2975)
Last 365 days (30168)
2026 (6791)
2025 (30467)
2024 (35501)
2023 (40412)
2022 (51563)
2021 (56019)
2020 (54385)
2019 (46882)
2018 (35263)
2017 (32444)
2016 (31808)
2015 (37826)
2014 (31565)
2013 (26687)
2012 (28866)
2011 (29580)
2010 (27605)
Location
Africa (742)
Alabama (87)
Alaska (7)
Arizona (324)
Arkansas (13)
Asia (40016)
Australia (6547)
California (12060)
Canada (3452)
China (1199)
Colorado (512)
Connecticut (516)
Delaware (357)
Europe (87015)
Florida (1814)
Georgia (384)
Hawaii (3)
Idaho (61)
Illinois (934)
India (75)
Indiana (552)
Iowa (22)
Japan (468)
Kansas (128)
Kentucky (43)
Louisiana (35)
Maine (73)
Maryland (1465)
Massachusetts (8685)
Michigan (340)
Minnesota (656)
Mississippi (6)
Missouri (135)
Montana (33)
Nebraska (29)
Nevada (133)
New Hampshire (82)
New Jersey (3189)
New Mexico (29)
New York (3177)
North Carolina (1547)
North Dakota (9)
Northern California (5949)
Ohio (356)
Oklahoma (22)
Oregon (44)
Pennsylvania (2428)
Puerto Rico (25)
Rhode Island (50)
South America (1122)
South Carolina (73)
South Dakota (1)
Southern California (4718)
Tennessee (195)
Texas (1871)
United States (42727)
Utah (362)
Vermont (1)
Virginia (282)
Washington D.C. (80)
Washington State (965)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
731,362 Results for "dice molecules sv inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate
Small-molecule drugs account for nearly half of the most valuable investigational therapies for orphan diseases, according to analytics firm Evaluate.
March 13, 2026
·
2 min read
·
Tristan Manalac
Press Releases
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
October 19, 2025
·
4 min read
Press Releases
Model Medicines to Present Ultra-Large Virtual Screening and Agentic AI Breakthroughs at AI Convergence: Small Molecule Discovery Summit
CEO, Daniel Haders II, PhD, to address the inference throughput barrier in AI-driven drug discovery and lead a roundtable on deploying LLMs and AI agents to navigate the multi-parameter optimization challenge in small molecule drug design
March 19, 2026
·
1 min read
Press Releases
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
June 2, 2025
·
7 min read
Press Releases
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
May 23, 2025
·
6 min read
Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
Syncromune ® Inc. today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research Annual Meeting 2024.
April 8, 2024
·
7 min read
Deals
Lilly Completes Acquisition of DICE Therapeutics
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).
August 9, 2023
·
4 min read
Press Releases
Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025
April 25, 2025
·
5 min read
Press Releases
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
March 18, 2026
·
3 min read
FDA
Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
Syncromune ® Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SYNC-T SV-102, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.
May 30, 2024
·
6 min read
1 of 73,137
Next
